

Identification of the natural ligand of an orphan G-protein-coupled receptor and the regulation of vasoconstriction

Nature Cell Biology

1, 383-385

DOI: [10.1038/14081](https://doi.org/10.1038/14081)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The physiological response to cardiovascular 'orphan' G protein-coupled receptor agonists. <i>Nature Medicine</i> , 1999, 5, 1241-1242.	15.2	12
2	Required reading. <i>Trends in Molecular Medicine</i> , 1999, 5, 466.	2.6	0
3	Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. <i>British Journal of Pharmacology</i> , 2000, 130, 1865-1870.	2.7	156
4	Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. <i>British Journal of Pharmacology</i> , 2000, 131, 441-446.	2.7	226
5	Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. <i>British Journal of Pharmacology</i> , 2000, 131, 1262-1274.	2.7	203
6	Human Urotensin-II, the Most Potent Mammalian Vasoconstrictor Identified To Date, as a Therapeutic Target for the Management of Cardiovascular Disease. <i>Trends in Cardiovascular Medicine</i> , 2000, 10, 229-237.	2.3	173
7	Human urotensin II mediates vasoconstriction via an increase in inositol phosphates. <i>European Journal of Pharmacology</i> , 2000, 406, 265-271.	1.7	99
8	Cortistatin: a member of the somatostatin neuropeptide family with distinct physiological functions. <i>Brain Research Reviews</i> , 2000, 33, 228-241.	9.1	182
9	Urotensin II: fish neuropeptide catches orphan receptor. <i>Trends in Pharmacological Sciences</i> , 2000, 21, 80-82.	4.0	48
10	Singular contributions of fish neuroendocrinology to mammalian regulatory peptide research. <i>Regulatory Peptides</i> , 2000, 93, 3-12.	1.9	35
11	Molecular Cloning and Characterization of a Second Human Cysteinyl Leukotriene Receptor: Discovery of a Subtype Selective Agonist. <i>Molecular Pharmacology</i> , 2000, 58, 1601-1608.	1.0	186
12	Discovery and mapping of ten novel G protein-coupled receptor genes. <i>Gene</i> , 2001, 275, 83-91.	1.0	172
13	Urotensin II-immunoreactivity in the brainstem and spinal cord of the rat. <i>Neuroscience Letters</i> , 2001, 305, 9-12.	1.0	63
14	Orphan G-protein-coupled receptors and natural ligand discovery. <i>Trends in Pharmacological Sciences</i> , 2001, 22, 132-140.	4.0	233
15	Novel neurotransmitters as natural ligands of orphan G-protein-coupled receptors. <i>Trends in Neurosciences</i> , 2001, 24, 230-237.	4.2	138
16	Identification of four novel human G protein-coupled receptors expressed in the brain. <i>Molecular Brain Research</i> , 2001, 86, 13-22.	2.5	69
17	Orphan G protein-coupled receptors in the CNS. <i>Current Opinion in Pharmacology</i> , 2001, 1, 31-39.	1.7	61
18	Urotensin II: a new mediator in cardiopulmonary regulation?. <i>Lancet, The</i> , 2001, 358, 774-775.	6.3	35

#	ARTICLE	IF	CITATIONS
19	Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. <i>Journal of Hypertension</i> , 2001, 19, 2185-2190.	0.3	216
20	Central effects of urotensin-II following ICV administration in rats. <i>Psychopharmacology</i> , 2001, 155, 426-433.	1.5	70
21	Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. <i>British Journal of Pharmacology</i> , 2001, 132, 1625-1629.	2.7	91
22	The urotensin II receptor is expressed in the cholinergic mesopontine tegmentum of the rat. <i>Brain Research</i> , 2001, 923, 120-127.	1.1	59
23	Effects of Urotensin II in Human Arteries and Veins of Varying Caliber. <i>Circulation</i> , 2001, 103, 1378-1381.	1.6	87
24	Human Urotensin II-Induced Contraction and Arterial Smooth Muscle Cell Proliferation Are Mediated by RhoA and Rho-Kinase. <i>Circulation Research</i> , 2001, 88, 1102-1104.	2.0	255
25	Localization of Urotensin-II Immunoreactivity in Normal Human Kidneys and Renal Carcinoma. <i>Journal of Histochemistry and Cytochemistry</i> , 2002, 50, 885-889.	1.3	100
26	High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. <i>Cardiovascular Research</i> , 2002, 53, 341-347.	1.8	86
27	Novel G-protein-coupled receptor genes expressed in the brain: continued discovery of important therapeutic targets. <i>Expert Opinion on Therapeutic Targets</i> , 2002, 6, 185-202.	1.5	17
28	A New, Potent Urotensin II Receptor Peptide Agonist Containing a Pen Residue at the Disulfide Bridge. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 4391-4394.	2.9	87
29	Discovery of the First Nonpeptide Agonist of the GPR14/Urotensin-II Receptor: Δ^3 -(4-Chlorophenyl)-3-(2- <i>Tj</i> ETQq0.0 rgBT /Overlock 1	2.9	63
30	UROTENSIN II MEDIATES ERK1/2 PHOSPHORYLATION AND PROLIFERATION IN GPR14-TRANSFECTED CELL LINES. <i>Journal of Receptor and Signal Transduction Research</i> , 2002, 22, 155-168.	1.3	50
31	Discovery of recently adopted orphan receptors for apelin, urotensin II, and ghrelin identified using novel radioligands and functional role in the human cardiovascular system. <i>Canadian Journal of Physiology and Pharmacology</i> , 2002, 80, 369-374.	0.7	59
32	Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure. <i>Regulatory Peptides</i> , 2002, 110, 33-38.	1.9	56
33	Target validation of G-protein coupled receptors. <i>Drug Discovery Today</i> , 2002, 7, 235-246.	3.2	347
34	Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2002, 365, 141-149.	1.4	92
35	Design, Synthesis, Conformational Analysis, and Biological Studies of Urotensin-II Lactam Analogues. <i>Bioorganic and Medicinal Chemistry</i> , 2002, 10, 3731-3739.	1.4	45
36	No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. <i>British Journal of Clinical Pharmacology</i> , 2002, 54, 617-621.	1.1	52

#	ARTICLE	IF	CITATIONS
37	Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. <i>British Journal of Pharmacology</i> , 2002, 136, 9-22.	2.7	120
38	A new ligand for the urotensin II receptor. <i>British Journal of Pharmacology</i> , 2002, 137, 311-314.	2.7	53
39	Is urotensin-II the new endothelin?. <i>British Journal of Pharmacology</i> , 2002, 137, 579-588.	2.7	115
40	Role of urotensin II gene in genetic susceptibility to Type 2 diabetes mellitus in Japanese subjects. <i>Diabetologia</i> , 2003, 46, 972-976.	2.9	85
41	Urotensin II: better than somatostatin for portal hypertension?. <i>Hepatology</i> , 2003, 31, 1201-1202.	3.6	7
42	The vasoactive peptide urotensin II stimulates spontaneous release from frog motor nerve terminals. <i>British Journal of Pharmacology</i> , 2003, 138, 1580-1588.	2.7	23
43	Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. <i>Biochemical and Biophysical Research Communications</i> , 2003, 310, 860-868.	1.0	151
44	Novel human G-protein-coupled receptors. <i>Biochemical and Biophysical Research Communications</i> , 2003, 305, 67-71.	1.0	51
45	The Expression of Urotensin II Receptor (U2R) is Upregulated by Interferon- β . <i>Journal of Receptor and Signal Transduction Research</i> , 2003, 23, 289-305.	1.3	35
46	Urotensin II Acts Centrally to Increase Epinephrine and ACTH Release and Cause Potent Inotropic and Chronotropic Actions. <i>Hypertension</i> , 2003, 42, 373-379.	1.3	85
47	Effect of human urotensin-II infusion on hemodynamics and cardiac function. <i>Canadian Journal of Physiology and Pharmacology</i> , 2003, 81, 125-128.	0.7	38
48	Production and Characterization of Monoclonal Antibodies against the Vasoconstrictive Peptide Human Urotensin-II. <i>Hybridoma</i> , 2003, 22, 377-382.	0.6	5
49	Structure-Activity Relationships of Human Urotensin II and Related Analogues on Rat Aortic Ring Contraction. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2003, 18, 77-88.	2.5	76
50	Chapter 11. Urotensin-II receptor modulators. <i>Annual Reports in Medicinal Chemistry</i> , 2003, 38, 99-110.	0.5	13
51	Urotensin II is an Autocrine/Paracrine Growth Factor for the Porcine Renal Epithelial Cell Line, LLCPK1. <i>Endocrinology</i> , 2003, 144, 1825-1831.	1.4	57
52	Central cardiovascular action of urotensin II in conscious rats. <i>Journal of Hypertension</i> , 2003, 21, 159-165.	0.3	54
54	Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. <i>American Journal of Physiology - Renal Physiology</i> , 2003, 285, F792-F798.	1.3	89
55	Photolabelling the rat urotensin II/GPR14 receptor identifies a ligand-binding site in the fourth transmembrane domain. <i>Biochemical Journal</i> , 2003, 370, 829-838.	1.7	44

#	ARTICLE	IF	CITATIONS
56	Urotensin II causes fatal circulatory collapse in anesthetized monkeys in vivo: a vasoconstrictor with a unique hemodynamic profile. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2004, 286, H830-H836.	1.5	36
57	Cortistatin- A Novel Member of the Somatostatin Gene Family. <i>Growth Hormone</i> , 2004, , 29-45.	0.2	2
58	Cellular distribution of GPR14 and the positive inotropic role of urotensin II in the myocardium in adult rat. <i>Journal of Applied Physiology</i> , 2004, 97, 2228-2235.	1.2	30
59	Postgenomic characterization of G-protein-coupled receptors. <i>Pharmacogenomics</i> , 2004, 5, 657-672.	0.6	33
60	Urotensin II Promotes Hypertrophy of Cardiac Myocytes via Mitogen-Activated Protein Kinases. <i>Molecular Endocrinology</i> , 2004, 18, 2344-2354.	3.7	84
62	Urotensin-II is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas. <i>European Journal of Endocrinology</i> , 2004, 151, 803-809.	1.9	44
63	Pharmacology of the Urotensin-II Receptor Antagonist Palosuran (ACT-058362); Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 512 Td (1-[2-(4-B Demonstration of a Pathophysiological Role of the Urotensin System. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 311, 204-212.	1.3	127
64	Regulation and function of somatostatin receptors. <i>Journal of Neurochemistry</i> , 2004, 89, 1057-1091.	2.1	300
65	Biochemical characterization and immunohistochemical localization of urotensin II in the human brainstem and spinal cord. <i>Journal of Neurochemistry</i> , 2004, 91, 110-118.	2.1	40
66	7 TM Receptors. <i>British Journal of Pharmacology</i> , 2004, 141, S5-S60.	2.7	1
67	Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines. <i>British Journal of Pharmacology</i> , 2004, 142, 921-932.	2.7	36
68	Emerging roles of urotensin-II in cardiovascular disease. , 2004, 103, 223-243.		58
69	Urotensin-II, a neuropeptide ligand for GPR14, induces c-fos in the rat brain. <i>European Journal of Pharmacology</i> , 2004, 493, 95-98.	1.7	7
70	Central effects of native urotensin II on motor activity, ventilatory movements, and heart rate in the trout <i>Oncorhynchus mykiss</i> . <i>Brain Research</i> , 2004, 1023, 167-174.	1.1	30
71	Urotensin II stimulates plasma extravasation in mice via UT receptor activation. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2004, 370, 347-352.	1.4	17
72	Urotensin-II receptor peptide agonists. <i>Medicinal Research Reviews</i> , 2004, 24, 577-588.	5.0	17
73	THE IDENTIFICATION OF LIGANDS AT ORPHAN-PROTEIN COUPLED RECEPTORS. <i>Annual Review of Pharmacology and Toxicology</i> , 2004, 44, 43-66.	4.2	208
74	Unraveling the Active Conformation of Urotensin II. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 1652-1661.	2.9	43

#	ARTICLE	IF	CITATIONS
75	Urotensin II: the old kid in town. Trends in Endocrinology and Metabolism, 2004, 15, 175-182.	3.1	64
76	From "gills to pills"™: urotensin-II as a regulator of mammalian cardiorenal function. Trends in Pharmacological Sciences, 2004, 25, 76-85.	4.0	141
77	Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides, 2004, 25, 1767-1774.	1.2	106
78	Role of urotensin II in peripheral tissue as an autocrine/paracrine growth factor. Peptides, 2004, 25, 1775-1781.	1.2	33
79	Genetic variations at urotensin II and urotensin II receptor genes and risk of type 2 diabetes mellitus in Japanese. Peptides, 2004, 25, 1803-1808.	1.2	46
80	Urotensin II, a novel peptide in central and peripheral cardiovascular control. Peptides, 2004, 25, 1759-1766.	1.2	33
81	Urotensin II in the cardiovascular system. Peptides, 2004, 25, 1795-1802.	1.2	37
82	Structure-activity relationships and structural conformation of a novel urotensin II-related peptide. Peptides, 2004, 25, 1819-1830.	1.2	95
83	Urotensin II and cardiovascular diseases. Peptides, 2004, 25, 1789-1794.	1.2	32
84	Urotensin II-related peptide, the endogenous ligand for the urotensin II receptor in the rat brain. Peptides, 2004, 25, 1815-1818.	1.2	19
85	The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease. Regulatory Peptides, 2004, 121, 129-136.	1.9	58
86	Intracerebroventricular administration of urotensin II promotes angiogenic-like behaviors in rodents. Neuroscience Letters, 2004, 358, 99-102.	1.0	36
87	Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. International Journal of Cardiology, 2004, 94, 93-97.	0.8	71
88	Human Urotensin II Modulates Collagen Synthesis and the Expression of MMP-1 in Human Endothelial Cells. Journal of Cardiovascular Pharmacology, 2004, 44, 577-581.	0.8	41
89	Isochromanone-based urotensin-II receptor agonists. Bioorganic and Medicinal Chemistry, 2005, 13, 3057-3068.	1.4	41
90	Urotensin II: Ancient Hormone with New Functions in Vertebrate Body Fluid Regulation. Annals of the New York Academy of Sciences, 2005, 1040, 66-73.	1.8	28
91	7 TM Receptors. British Journal of Pharmacology, 2005, 144, S4-S62.	2.7	2
92	From heart to mind. FEBS Journal, 2005, 272, 5694-5702.	2.2	19

#	ARTICLE	IF	CITATIONS
93	Inhibitory effects of putative peptidic urotensin-II receptor antagonists on urotensin-II-induced contraction of cat isolated respiratory smooth muscle. <i>European Journal of Pharmacology</i> , 2005, 516, 276-281.	1.7	7
94	Cloning and pharmacological characterization of the cat urotensin-II receptor (UT). <i>Biochemical Pharmacology</i> , 2005, 69, 1069-1079.	2.0	18
95	Urotensin II acts as a modulator of mesopontine cholinergic neurons. <i>Brain Research</i> , 2005, 1059, 139-148.	1.1	20
96	Behavioral effects of urotensin-II centrally administered in mice. <i>Psychopharmacology</i> , 2005, 183, 103-117.	1.5	47
97	Urotensin-II levels in children with minimal change nephrotic syndrome. <i>Pediatric Nephrology</i> , 2005, 20, 42-45.	0.9	16
98	Structure-activity relationship study on human urotensin II. <i>Journal of Peptide Science</i> , 2005, 11, 85-90.	0.8	34
99	Discovery of Novel Regulatory Peptides by Reverse Pharmacology: Spotlight on Chemerin and the RF-amide Peptides Metastin and QRFP. <i>Current Protein and Peptide Science</i> , 2005, 6, 265-278.	0.7	21
100	The G Protein-Coupled Receptors Handbook. <i>Contemporary Clinical Neuroscience</i> , 2005, , .	0.3	5
101	Arrestin-Independent Internalization and Recycling of the Urotensin Receptor Contribute to Long-Lasting Urotensin II-Mediated Vasoconstriction. <i>Circulation Research</i> , 2005, 97, 707-715.	2.0	36
102	G-Protein-Coupled Receptor Deorphanizations. <i>International Review of Neurobiology</i> , 2005, 65, 179-209.	0.9	7
103	Urotensin II Modulates Rapid Eye Movement Sleep through Activation of Brainstem Cholinergic Neurons. <i>Journal of Neuroscience</i> , 2005, 25, 5465-5474.	1.7	72
104	Architecture of the Human Urotensin II Receptor: A Comparison of the Binding Domains of Peptide and Non-Peptide Urotensin II Agonists. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 2480-2492.	2.9	30
105	A novel hypothalamic neuroendocrine peptide: URP (urotensin-II-related peptide)? <i>Comptes Rendus - Biologies</i> , 2005, 328, 724-731.	0.1	11
106	Proliferation and anti-apoptotic effects of human urotensin II on human endothelial cells. <i>Atherosclerosis</i> , 2006, 188, 260-264.	0.4	50
107	Structure-Activity Relationships of a Novel Series of Urotensin II Analogues: Identification of a Urotensin II Antagonist. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 7234-7238.	2.9	30
108	Urotensin-II expression in the mouse spinal cord. <i>Journal of Chemical Neuroanatomy</i> , 2006, 31, 146-154.	1.0	19
109	Alteration of vascular urotensin II receptor in mice with apolipoprotein E gene knockout. <i>Peptides</i> , 2006, 27, 858-863.	1.2	25
110	Identification and characterization of binding sites for human urotensin-II in Sprague-Dawley rat renal medulla using quantitative receptor autoradiography. <i>Peptides</i> , 2006, 27, 1532-1537.	1.2	14

#	ARTICLE	IF	CITATIONS
111	Urotensin II and Urotensin IIâ€‘Related Peptide. , 2006, , 795-803.		2
112	Urotensin-II and its receptor (UT-R) are expressed in rat brain endothelial cells, and urotensin-II via UT-R stimulates angiogenesis in vivo and in vitro. International Journal of Molecular Medicine, 2006, 18, 1107.	1.8	7
113	Renal effects of human urotensin-II in rats with experimental congestive heart failure. Nephrology Dialysis Transplantation, 2006, 21, 1205-1211.	0.4	24
114	Non-peptidic urotensin-II receptor modulators. Expert Opinion on Therapeutic Patents, 2006, 16, 467-479.	2.4	11
115	Altered neuropeptide processing in prefrontal cortex of Cpefat/fat mice: implications for neuropeptide discovery. Journal of Neurochemistry, 2006, 96, 1169-1181.	2.1	51
116	Biochemical and functional characterization of high-affinity urotensinâ€™ll receptors in rat cortical astrocytes. Journal of Neurochemistry, 2006, 99, 582-595.	2.1	50
117	7 TM RECEPTORS. British Journal of Pharmacology, 2006, 147, S5-S81.	2.7	1
118	The role of urotensin II in cardiovascular and renal physiology and diseases. British Journal of Pharmacology, 2006, 148, 884-901.	2.7	65
119	Urotensin II and renal function in the rat. Kidney International, 2006, 69, 1360-1368.	2.6	61
120	Salusin Î² is a surrogate ligand of the mas-like G protein-coupled receptor MrgA1. European Journal of Pharmacology, 2006, 539, 145-150.	1.7	34
121	Localization of the urotensin II receptor in the rat central nervous system. Journal of Comparative Neurology, 2006, 495, 21-36.	0.9	60
122	Comparative genomics provides evidence for close evolutionary relationships between the urotensin II and somatostatin gene families. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2237-2242.	3.3	87
123	Photolabelling the urotensin II receptor reveals distinct agonist- and partial-agonist-binding sites. Biochemical Journal, 2007, 402, 51-61.	1.7	15
124	Orphan Seven Transmembrane Receptor Screening. Ernst Schering Research Foundation Workshop, 2007, , 105-144.	0.7	6
125	QSAR Modeling of GPCR Ligands: Methodologies and Examples of Applications. Ernst Schering Research Foundation Workshop, 2007, , 49-74.	0.7	13
126	Cardiovascular Activity. , 2007, , 47-391.		1
127	7TM Receptors. British Journal of Pharmacology, 2007, 150, S4-S81.	2.7	10
128	Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension. Liver International, 2007, 27, 1232-1239.	1.9	24

#	ARTICLE	IF	CITATIONS
129	Fusion of diphtheria toxin and urotensin II produces a neurotoxin selective for cholinergic neurons in the rat mesopontine tegmentum. <i>Journal of Neurochemistry</i> , 2007, 102, 112-120.	2.1	31
130	7TM Receptors. <i>British Journal of Pharmacology</i> , 2008, 153, S4-S95.	2.7	2
131	Urotensin II: Lessons from comparative studies for general endocrinology. <i>General and Comparative Endocrinology</i> , 2008, 157, 14-20.	0.8	14
132	âœLiberationâœ of urotensin II from the teleost urophysis: An historical overview. <i>Peptides</i> , 2008, 29, 651-657.	1.2	21
133	Another ligand fishing for G protein-coupled receptor 14. <i>Peptides</i> , 2008, 29, 809-812.	1.2	31
134	Central and peripheral cardiovascular, ventilatory, and motor effects of trout urotensin-II in the trout. <i>Peptides</i> , 2008, 29, 830-837.	1.2	25
135	Immunolocalization of urotensin II and its receptor in human adrenal tumors and attached non-neoplastic adrenal tissues. <i>Peptides</i> , 2008, 29, 873-880.	1.2	29
136	Structureâœactivity relationships of urotensin II and URP. <i>Peptides</i> , 2008, 29, 658-673.	1.2	56
137	Increased circulating urotensin II in cirrhosis: Potential implications in liver disease. <i>Peptides</i> , 2008, 29, 868-872.	1.2	13
138	Evidence for endogenous urotensin-II as an inhibitor of insulin secretion. <i>Peptides</i> , 2008, 29, 852-858.	1.2	16
139	Urotensin-II and cardiovascular remodeling. <i>Peptides</i> , 2008, 29, 764-769.	1.2	39
140	[Orn5]URP acts as a pure antagonist of urotensinergic receptors in rat cortical astrocytes. <i>Peptides</i> , 2008, 29, 813-819.	1.2	8
141	Urotensin II and urotensin II-related peptide activate somatostatin receptor subtypes 2 and 5. <i>Peptides</i> , 2008, 29, 711-720.	1.2	30
142	Behavioral actions of urotensin-II. <i>Peptides</i> , 2008, 29, 838-844.	1.2	26
143	State-dependent calcium mobilization by urotensin-II in cultured human endothelial cells. <i>Peptides</i> , 2008, 29, 721-726.	1.2	13
144	Editorial. <i>Peptides</i> , 2008, 29, 647-648.	1.2	3
145	Neuropeptide interactions and REM sleep: A role for Urotensin II?. <i>Peptides</i> , 2008, 29, 845-851.	1.2	16
146	Effects of urotensin-II on cerebral blood flow and ischemia in anesthetized rats. <i>Experimental Neurology</i> , 2008, 210, 577-584.	2.0	11

#	ARTICLE	IF	CITATIONS
147	Cortistatinâ€™Functions in the central nervous system. <i>Molecular and Cellular Endocrinology</i> , 2008, 286, 88-95.	1.6	62
148	New insight into the molecular evolution of the somatostatin family. <i>Molecular and Cellular Endocrinology</i> , 2008, 286, 5-17.	1.6	66
149	Urotensin II in chronic liver disease:<i>In vivo</i>effect on vascular tone. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 103-109.	0.6	6
150	Enhanced renal sensitivity of the spontaneously hypertensive rat to urotensin II. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 295, F1239-F1247.	1.3	12
151	Renal haemodynamic and tubular actions of urotensin II in the rat. <i>Journal of Endocrinology</i> , 2008, 198, 617-624.	1.2	18
152	Urotensin II in cardiovascular regulation. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 775-785.	1.0	29
153	Human Urotensin II Promotes Hypertension and Atherosclerotic Cardiovascular Diseases. <i>Current Medicinal Chemistry</i> , 2009, 16, 550-563.	1.2	44
154	Urotensin II modulates hepatic fibrosis and portal hemodynamic alterations in rats. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 297, G762-G767.	1.6	18
155	Urotensin II Immunoreactivity in the Human Circulation: Evidence for Widespread Tissue Release. <i>Clinical Chemistry</i> , 2009, 55, 2040-2048.	1.5	15
156	7TM RECEPTORS. <i>British Journal of Pharmacology</i> , 2009, 158, S5.	2.7	2
157	Characterization of the insulinostatic effect of urotensin II: A study in the perfused rat pancreas. <i>Regulatory Peptides</i> , 2009, 153, 37-42.	1.9	9
158	Pro-angiogenic activity of Urotensin-II on different human vascular endothelial cell populations. <i>Regulatory Peptides</i> , 2009, 157, 64-71.	1.9	17
159	The vasoactive peptides urotensin II and urotensin II-related peptide regulate astrocyte activity through common and distinct mechanisms: involvement in cell proliferation. <i>Biochemical Journal</i> , 2010, 428, 113-124.	1.7	50
160	Novel Octreotide Dicarba-analogues with High Affinity and Different Selectivity for Somatostatin Receptors. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 6188-6197.	2.9	32
161	Effect of Urotensin II on PC12 Rat Pheochromocytoma Cells. <i>Journal of Neuroendocrinology</i> , 2010, 22, 83-91.	1.2	10
162	Role of urotensin II in health and disease. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2010, 298, R1156-R1172.	0.9	113
163	Urotensin II, from fish to human. <i>Annals of the New York Academy of Sciences</i> , 2010, 1200, 53-66.	1.8	90
164	Urotensin II receptor antagonist attenuates monocrotaline-induced cardiac hypertrophy in rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010, 299, H1782-H1789.	1.5	14

#	ARTICLE	IF	CITATIONS
165	Urotensin-II Receptor Modulators as Potential Drugs. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 2695-2708.	2.9	50
166	Urotensin II stimulates high frequency-induced ANP secretion via PLC-PI 3K-PKC pathway. <i>Peptides</i> , 2010, 31, 164-169.	1.2	5
167	Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioliomyomatosis. <i>Peptides</i> , 2010, 31, 1511-1516.	1.2	13
168	Urotensin II receptor and acetylcholine release from mouse cervical spinal cord nerve terminals. <i>Neuroscience</i> , 2010, 170, 67-77.	1.1	17
169	Urotensin-2 promotes collagen synthesis via ERK1/2-dependent and ERK1/2-independent TGF- β 1 in neonatal cardiac fibroblasts. <i>Cell Biology International</i> , 2011, 35, 93-98.	1.4	22
170	Urotensin II differentially regulates macrophage and hepatic cholesterol homeostasis. <i>Peptides</i> , 2011, 32, 956-963.	1.2	18
171	Urotensin II Levels Are an Important Marker for the Severity of Portal Hypertension in Children. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2011, 53, 88-92.	0.9	9
172	Novel Neuropeptides as Ligands of Orphan G Protein-Coupled Receptors. <i>Current Pharmaceutical Design</i> , 2011, 17, 2626-2631.	0.9	9
173	Guide to Receptors and Channels (GRAC), 5th edition. <i>British Journal of Pharmacology</i> , 2011, 164, S1-324.	2.7	827
174	Consultants. <i>British Journal of Pharmacology</i> , 2011, 164, S3-S3.	2.7	10
175	G PROTEIN-COUPLED RECEPTORS. <i>British Journal of Pharmacology</i> , 2011, 164, S5.	2.7	16
176	LIGAND-GATED ION CHANNELS. <i>British Journal of Pharmacology</i> , 2011, 164, S115.	2.7	13
177	ION CHANNELS. <i>British Journal of Pharmacology</i> , 2011, 164, S137.	2.7	22
178	NUCLEAR RECEPTORS. <i>British Journal of Pharmacology</i> , 2011, 164, S175-S188.	2.7	0
179	CATALYTIC RECEPTORS. <i>British Journal of Pharmacology</i> , 2011, 164, S189-S212.	2.7	1
180	TRANSPORTERS. <i>British Journal of Pharmacology</i> , 2011, 164, S213.	2.7	2
182	Occurrence of Two Distinct Urotensin II-Related Peptides in Zebrafish Provides New Insight into the Evolutionary History of the Urotensin II Gene Family. <i>Endocrinology</i> , 2011, 152, 2330-2341.	1.4	35
183	Urotensin II and its receptor in the killifish gill: regulators of NaCl extrusion. <i>Journal of Experimental Biology</i> , 2011, 214, 3985-3991.	0.8	19

#	ARTICLE	IF	CITATIONS
184	Urotensin-II: More Than a Mediator for Kidney. <i>International Journal of Nephrology</i> , 2012, 2012, 1-7.	0.7	8
185	Genetic and Pharmacological Manipulation of Urotensin II Ameliorate the Metabolic and Atherosclerosis Sequelae in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 1809-1816.	1.1	43
186	Urotensin II protects ischemic reperfusion injury of hearts through ROS and antioxidant pathway. <i>Peptides</i> , 2012, 36, 199-205.	1.2	14
187	Down-Regulation of GABAA Receptor via Promiscuity with the Vasoactive Peptide Urotensin II Receptor. Potential Involvement in Astrocyte Plasticity. <i>PLoS ONE</i> , 2012, 7, e36319.	1.1	11
188	Characterization of the true ortholog of the urotensin II-related peptide (URP) gene in teleosts. <i>General and Comparative Endocrinology</i> , 2012, 177, 205-212.	0.8	19
189	Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes. <i>Diabetologia</i> , 2013, 56, 1155-1165.	2.9	34
190	Impact of gene/genome duplications on the evolution of the urotensin II and somatostatin families. <i>General and Comparative Endocrinology</i> , 2013, 188, 110-117.	0.8	31
191	The Concise Guide to PHARMACOLOGY 2013/14: G Proteinâ€Coupled Receptors. <i>British Journal of Pharmacology</i> , 2013, 170, 1459-1581.	2.7	528
192	Update on the urotensinergic system: new trends in receptor localization, activation, and drug design. <i>Frontiers in Endocrinology</i> , 2013, 3, 174.	1.5	21
193	Urotensin II and the kidney. <i>Current Opinion in Nephrology and Hypertension</i> , 2013, 22, 107-112.	1.0	7
194	Urotensin-II Ligands: An Overview from Peptide to Nonpeptide Structures. <i>Journal of Amino Acids</i> , 2013, 2013, 1-15.	5.8	13
195	Urotensin II Induces Interleukin 8 Expression in Human Umbilical Vein Endothelial Cells. <i>PLoS ONE</i> , 2014, 9, e90278.	1.1	18
196	Urotensinâ€receptor is overâ€expressed in colon cancer cell lines and in colon carcinoma in humans. <i>European Journal of Clinical Investigation</i> , 2014, 44, 285-294.	1.7	22
197	Blocking the urotensin II receptor pathway ameliorates the metabolic syndrome and improves cardiac function in obese mice. <i>FASEB Journal</i> , 2014, 28, 1210-1220.	0.2	15
198	RGS2 Regulates Urotensin IIâ€Induced Intracellular Ca ²⁺ Elevation and Contraction in Glomerular Mesangial Cells. <i>Journal of Cellular Physiology</i> , 2014, 229, 502-511.	2.0	22
199	Concordant localization of functional urotensin II and urotensin IIâ€related peptide binding sites in the rat brain: Atypical occurrence close to the fourth ventricle. <i>Journal of Comparative Neurology</i> , 2014, 522, 2634-2649.	0.9	3
200	Therapeutic implications of peptide interactions with Gâ€proteinâ€coupled receptors in diabetic vasculopathy. <i>Acta Physiologica</i> , 2014, 211, 20-35.	1.8	9
201	MOLECULAR EVOLUTION OF GPCRS: Somatostatin/urotensin II receptors. <i>Journal of Molecular Endocrinology</i> , 2014, 52, T61-T86.	1.1	54

#	ARTICLE	IF	CITATIONS
202	Lead Optimization of P5U and Urantide: Discovery of Novel Potent Ligands at the Urotensin-II Receptor. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 5965-5974.	2.9	21
203	The Ull/UT System Mediates Upregulation of Proinflammatory Cytokines through p38 MAPK and NF- κ B Pathways in LPS-Stimulated Kupffer Cells. <i>PLoS ONE</i> , 2015, 10, e0121383.	1.1	34
204	Comparative Distribution and In Vitro Activities of the Urotensin II-Related Peptides URP1 and URP2 in Zebrafish: Evidence for Their Colocalization in Spinal Cerebrospinal Fluid-Contacting Neurons. <i>PLoS ONE</i> , 2015, 10, e0119290.	1.1	45
205	Signaling switch of the urotensin II vasosactive peptide GPCR: prototypic chemotaxic mechanism in glioma. <i>Oncogene</i> , 2015, 34, 5080-5094.	2.6	17
206	International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, Urotensin II-Related Peptide, and Their Receptor: From Structure to Function. <i>Pharmacological Reviews</i> , 2015, 67, 214-258.	7.1	82
207	Intra-ventral tegmental area microinjections of urotensin II modulate the effects of cocaine. <i>Behavioural Brain Research</i> , 2015, 278, 271-279.	1.2	2
208	Biochemical and physiological effects from exhaust emissions. A review of the relevant literature. <i>Pathophysiology</i> , 2016, 23, 285-293.	1.0	21
209	Conformation and Dynamics of Human Urotensin II and Urotensin Related Peptide in Aqueous Solution. <i>Journal of Chemical Information and Modeling</i> , 2017, 57, 298-310.	2.5	12
210	Study of urotensin-2 (T21M and S89N) gene polymorphisms in systemic sclerosis. <i>Meta Gene</i> , 2017, 12, 125-129.	0.3	1
211	Age-Related Reduction of Contractile Responses to Urotensin II Is Seen in Aortas from Wistar Rats but Not from Type 2 Diabetic Goto-Kakizaki Rats. <i>Rejuvenation Research</i> , 2017, 20, 134-145.	0.9	3
212	Urotensin II Exerts Pressor Effects By Stimulating Renin And Aldosterone Synthase Gene Expression. <i>Scientific Reports</i> , 2017, 7, 13876.	1.6	4
213	UTS2 (urotensin 2). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2017, , .	0.1	0
214	Acute Effect of Central Administration of Urotensin II on Baroreflex and Blood Pressure in Conscious Normotensive Rabbits. <i>Frontiers in Physiology</i> , 2017, 8, 110.	1.3	0
215	The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features. <i>Frontiers in Endocrinology</i> , 2017, 8, 76.	1.5	22
216	Discovery of New Allosteric Modulators of the Urotensinergic System through Substitution of the Urotensin II-Related Peptide (URP) Phenylalanine Residue. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8707-8716.	2.9	12
217	Chronic Urotensin-II Administration Improves Whole-Body Glucose Tolerance in High-Fat Diet-Fed Mice. <i>Frontiers in Endocrinology</i> , 2019, 10, 453.	1.5	6
218	Novel insights into the role of urotensin II in cardiovascular disease. <i>Drug Discovery Today</i> , 2019, 24, 2170-2180.	3.2	18
219	Microinjection of urotensin II into the pedunculo-pontine tegmentum leads to an increase in the consumption of sweet tastants. <i>Physiology and Behavior</i> , 2020, 215, 112775.	1.0	0

#	ARTICLE	IF	CITATIONS
220	Identification and signaling characterization of four urotensin II receptor subtypes in the western clawed frog, <i>Xenopus tropicalis</i> . <i>General and Comparative Endocrinology</i> , 2020, 299, 113586.	0.8	4
221	Characterization of four urotensin II receptors (UTS2Rs) in chickens. <i>Peptides</i> , 2021, 138, 170482.	1.2	6
222	Conserved role of the urotensin II receptor 4 signalling pathway to control body straightness in a tetrapod. <i>Open Biology</i> , 2021, 11, 210065.	1.5	9
223	Blocking of urotensin receptors as new target for treatment of carrageenan induced inflammation in rats. <i>Peptides</i> , 2016, 82, 35-43.	1.2	17
224	Urotensin II: an inflammatory cytokine. <i>Journal of Endocrinology</i> , 2019, 240, R107-R117.	1.2	17
225	IRF3 is an important molecule in the Ull/UT system and mediates immune inflammatory injury in acute liver failure. <i>Oncotarget</i> , 2016, 7, 49027-49041.	0.8	13
226	Oncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2. <i>Oncotarget</i> , 2016, 7, 61152-61165.	0.8	5
227	Urotensin-II Receptor: A Double Identity Receptor Involved in Vasoconstriction and in the Development of Digestive Tract Cancers and other Tumors. <i>Current Cancer Drug Targets</i> , 2017, 17, 109-121.	0.8	17
228	Urotensin II receptor expression in patients with ulcerative colitis: a pilot study. <i>Minerva Gastroenterologica E Dietologica</i> , 2020, 66, 23-28.	2.2	3
229	Effect of urotensin II on apolipoprotein B100 and apolipoprotein A-I expression in HepG2 cell line. <i>Advanced Biomedical Research</i> , 2014, 3, 22.	0.2	2
230	Urotensin II-related peptide (Urp) is expressed in motoneurons in zebrafish, but is dispensable for locomotion in larva. <i>Peptides</i> , 2021, 146, 170675.	1.2	6
231	Urotensin-II. <i>British Journal of Pharmacology</i> , 2006, , S79-S79.	2.7	0
232	Urotensin-II Receptor. , 2007, , 1-5.		0
233	Urotensin-II. <i>British Journal of Pharmacology</i> , 2009, 158, S98-S98.	2.7	0
234	Receptor Identification: Advances in Ligands and Transmitters Discovery. <i>Journal of Pharmaceutical Technology Research and Management</i> , 2014, 2, 61-75.	0.3	0
235	Effect of Different Peptides. , 2015, , 1-45.		0
236	Effect of Different Peptides. , 2016, , 513-553.		0
238	De-Orphanizing GPCRs and Drug Development. <i>Contemporary Clinical Neuroscience</i> , 2005, , 389-401.	0.3	0

#	ARTICLE	IF	CITATIONS
239	Urotensin-II and endothelin-I levels after contrast media administration in patients undergoing percutaneous coronary interventions. Journal of Research in Medical Sciences, 2013, 18, 205-9.	0.4	10
242	Urotensin II-related peptides, Urp1 and Urp2, control zebrafish spine morphology. ELife, 0, 11, .	2.8	16